Nav: Home

Northeastern partners with leading immunologist to uncover protein linked to cancer

September 07, 2016

There is a lot involved in the discovery of new drugs to fight disease. What's important to remember is the immense amount of fundamental research that is vital to ultimately paving the way to new types of therapeutics.

Starting from the beginning means identifying how a protein structure is built, how it moves, and how it communicates with other proteins and cells in the body. In a recently funded project involving Boston Children's Hospital and Northeastern University, chemistry Professors John R. Engen and Roxana Iacob have teamed up with Prof. Timothy A. Springer--a renowned immunologist and structural biologist from Harvard Medical School (HMS) and Boston Children's Hospital--to uncover the inner-workings of an extremely complex class of proteins. Understanding these proteins could eventually lead to the development of drugs designed to treat diseases such as cancer, heart disease, and diabetes.

Transforming Growth Factor (TGF) beta is a member of the TGF-β superfamily of cytokines, which is made up of proteins that bind to receptors on certain certain cells and cause messages inside those cells to be sent. TGF-β contributes to many cellular functions, such as cell growth, but there is not enough known about this protein family. "It's hard to solve the structure and understand how they all work because TGF-β and it's relatives are very complicated," said Engen.

Despite the intricacies, understanding the inner workings of TGF-β is critical due to its role in many diseases, including cancer.

Similar to behaviors observed with integrins, also a protein Springer studies, TGF-β transmits information from the outside that will instruct the cell to grow, divide, or kill itself. TGF-β is related to many cancers because it's susceptible to misinforming cells to proliferate even when they shouldn't, and it's those misfires that cause disease.

With Springer's expertise in signal transduction across membranes and Engen and Iacob's experience in Hydrogen/Deuterium Exchange Mass Spectrometry (HDX MS)--a method championed by Prof. Engen--the team hopes to better understand the structural and dynamic aspects of TGF-β superfamily.

Early in 2014, through another collaborator from HMS, Prof. Springer and Profs. Engen and Iacob met to start a collaboration on the TGF-β superfamily. "Basically, we met and he described the complexity and the challenges of this project and we were intrigued by the opportunities that this research could lead to, especially using HDX MS. So we agreed to start working on the project right away" Iacob said.

Iacob has now worked on 10 family members in the 33-member TGF-β superfamily. Amongst those, a very interesting protein Bone Morphogenic Protein (BMP) was studied - a protein used during procedures such as hip replacements to promote bone growth. The Springer lab has been performing electron microscopy on some of these family members, and the technique used by Engen and Iacob will be able to uncover additional information needed to learn about the inner workings of the TGF-β superfamily.

The objective of the recently funded grant that supports this project is to work around the family tree for these proteins. "The goal of the project is to understand, structurally, what happens with this protein (TGF-β) and other family members," said Iacob. "It's fundamental research for now, but it's very important because, based on our findings, it will be easier to create therapies."

"All of (the proteins) are drug targets," said Engen. "You can name many diseases, and these proteins are likely connected somehow. Some of the proteins are involved in the immune system, some of them are involved in bone growth, others in embryonic development."
-end-


Northeastern University College of Science

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...